A high level of C3 expression suggested a good outcome for immune checkpoint blockade (ICB) therapy targeting PD1, CTLA4, and ACT in melanoma, but a bad outcome for ICB therapy targeting PD1 and PDL1 in GBM and bladder cancer. This evidence concerns the gene CTLA4 and melanoma.